Articles tagged with Cell Therapies
Seven high-impact studies will be showcased, exploring novel therapies and improving treatment outcomes for patients with head and neck squamous cell carcinoma. These findings highlight advancements in immunotherapy, risk-directed adjuvant therapy, and FDG-PET-based selective de-escalation of radiotherapy.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
Researchers developed an oxidative stress-based prognostic model for bladder cancer, identifying distinct molecular subtypes and predicting patient outcomes. The model shows promise in tailoring personalized treatment approaches, particularly for patients with low-risk profiles.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
The Almodóvar lab is studying the link between HIV and pulmonary hypertension, a condition that increases pressure in lung arteries. By examining the interactions between different cell types and using a humanized mouse model, researchers hope to propose novel therapies to prevent lung diseases in people with HIV.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
A team of researchers from the University of Tokyo demonstrated that a drug, valemetostat, reduces tumor growth in blood cancer by targeting H3K27me3, a protein modification silencing tumor suppressor genes. The treatment restores expression of many tumor suppressor genes and sustains inhibiting tumor cell growth.
Researchers developed a CRISPR RNA-editing platform to regulate immune cell metabolism, boosting anti-tumor function and sustaining T cell proliferation. The platform enables reversible changes to gene expression and can be controlled by a drug, offering a safety switch for immunotherapy treatments.
Scientists create 'μkiss' technique for precise delivery of materials to individual cells, offering new possibilities in single-cell science and next-generation therapeutic applications. The method provides full control over location, time, and scale of material application, enabling detailed studies of cellular processes.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
Researchers develop nanovector nanogels that selectively target glial cells involved in spinal cord injury inflammation, reducing damage and improving recovery. The treatment demonstrates potential for modulating glial cells in neurodegenerative diseases like Alzheimer's.
A recent study has uncovered 145 genes crucial for genome stability, shedding light on genetic factors influencing human health over a lifespan. The research highlights the potential of SIRT inhibitors as a therapeutic pathway for cohesinopathies and other genomic disorders.
Researchers have developed a new immunotherapy based on STAb cells that outperforms existing CAR-T treatment in laboratory trials. The new therapy recruits natural T cells to fight cancer cells and overcomes limitations of current treatments.
Researchers at the University of Minnesota Medical School have explored a new approach to combat HIV by enhancing Natural Killer cell function. The study found that providing healthy NK cells and an anti-HIV drug resulted in significant reductions in infection burden, offering a potential cure strategy.
Researchers found significantly higher levels of IL-18 expression in osteoarthritis patients and cells compared to healthy controls. IL-17 promoted IL-18 production through the MEK/ERK/miR-4492 axis, indicating potential therapeutic targets for OA treatment.
Researchers created an additional means for therapy to find and eliminate cancer cells using a small peptide, demonstrating better efficacy in lab tests and in vitro experiments. The study used computational analysis and predicted protein models to understand how structure impacts antigen recognition and therapy efficacy.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Researchers found elevated PROX1 levels in advanced colon adenocarcinoma, correlating with poor prognosis. PROX1 modulates CRC cell behavior, influencing invasiveness and survival outcomes. The combined PROX1/α-SMA gene set emerges as a potential CRC prognostic marker.
A microfluidic chip can remove undifferentiated cells that could form tumors before they are implanted in a patient, improving the safety and effectiveness of cell therapy. The device can sort over 3 million cells per minute without causing damage to fully-formed progenitor cells.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.
Researchers from Tokyo University of Science identify Cpeb4 protein's crucial role in mRNA splicing and osteoclast differentiation, shedding light on bone disease mechanisms. The study's findings may lead to new diagnostic techniques and treatments for conditions like osteoporosis.
Researchers at Germans Trias i Pujol Research Institute have identified a combination of drugs that could change the treatment of patients with prostate cancer resistant to docetaxel. The study proposes a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.
Researchers at Memorial Sloan Kettering Cancer Center have engineered CAR T cells to target senescent cells, which can lead to chronic inflammation with aging. The treatment improved metabolic function in older mice and prevented decline later in life, suggesting potential benefits for diseases associated with aging.
Researchers discovered a new role for Mfsd7c in exporting excessive choline from the brain. The study suggests that targeting this protein could lead to therapeutic interventions for Alzheimer's disease and other neurological disorders.
A phase II clinical trial found Muse cell-based product CL2020 to be highly tolerated and improved ALS symptoms, but may not halt disease progression. The treatment's efficacy depends on combining it with other drugs for future treatments.
A new CRISPR delivery method enables precise targeting of specific cell subsets in living animals, paving the way for programmable gene therapy. The system uses antibody-targeted 'enveloped delivery vehicles' to selectively edit T-cells and create CAR T-cells.
Researchers have uncovered the molecular and ultrastructural features of BCAS1+ cells in diffuse gliomas, highlighting their proliferative capacity and distribution. The study provides a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas, shedding light on its role in tumor malignancy.
Northwestern University researchers successfully engineered a virus to destroy itself from the inside out, killing a deadly bacterium. The study represents a critical step towards creating new therapies to treat antibiotic-resistant infections.
Researchers identified senescence-related tumor microenvironment genes associated with poor prognosis, genetic alterations, and reduced responsiveness to immunotherapy in HNSC. The study highlights the importance of precision medicine approaches for personalized treatment.
A study reveals thyroid cancer's genetic changes contribute to resistance to BRAF inhibitors and can lead to tumor dedifferentiation. Researchers identify potential targets for new therapies, including dual-targeted treatments and immunotherapy combinations.
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
Researchers found that low-dose X-ray irradiation reduced lesion size and reversed motor deficits in TBI and ischemic stroke mice, demonstrating its potential as a therapeutic strategy. The treatment also accelerated substantial motor function recovery and promoted brain rewiring after stroke.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers report a case of a patient with EGFR L858R mutant non-small cell lung cancer (NSCLC) who experienced durable disease improvement after empirical treatment with osimertinib. The 'Lazarus effect' refers to the phenomenon where cancer appears to recur after seeming to be in remission.
A new study published in Neurology found that young Black and Hispanic women with multiple sclerosis face greater challenges in pregnancy, have more advanced disease, and experience higher inflammation levels, which may signal MS progression. The researchers also noted disparities in healthcare access and treatment.
A new 3D bioprinted liver tissue model has been developed to study nonalcoholic steatohepatitis (NASH), a serious complication of nonalcoholic fatty liver disease (NAFLD). The model, created using liver cells from healthy or NASH-diseased donors, displays all characteristics of the disease, including fibrosis.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
Researchers have developed CRISPR off-switches to mitigate off-target effects, a major concern in genome editing. The new technology, based on anti-CRISPR proteins, can block CRISPR-Cas3 machine function and prevent unintended edits.
Researchers from Miami Cancer Institute published a study analyzing the use of tissue-agnostic therapeutics in patients with primary brain tumors. The publication discusses data from clinical trials and additional tissue-agnostic targets that hold promise for benefiting patients with PBTs.
Researchers found that bone marrow mononuclear cell infusion in children within 48 hours of severe traumatic brain injury reduced intensive care needs and preserved white matter. The treatment also enhanced connectivity in the corpus callosum, a midline structure in the brain.
Researchers at Cleveland Clinic have developed a peptide therapeutic that blocks aggressive cancer cells from multiplying rapidly. The treatment disrupts the molecular processes behind cancer growth and induces tumor cell death, making it a promising new strategy for treating triple-negative breast cancer.
Researchers at Nagoya University have discovered a relationship between ALS progression and the disruption of mitochondria-associated membranes (MAM) and TBK1 activity. Decreased activation of TBK1 is linked to motor neuron death in ALS patients and mice with disrupted MAM.
Researchers from Tokyo University of Science discovered that manipulating polyamines enhances the functional profiles of monoclonal antibodies. The study found that controlling polyamine levels increases IgG galactosylation, leading to improved therapeutic efficacy.
Researchers at St. Jude Children's Research Hospital have developed a molecular glue that sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to its destruction. The compound, SJ3149, displays broad anti-cancer activity and may have clinical utility as an alternative to conventional small molecule inhibitors.
A study by the University of Sheffield found that breast cancer cells take advantage of nutrients in the extracellular matrix when faced with nutrient starvation. The cells use an ingestion process called macropinocytosis to consume the matrix, breaking it down into energy-releasing substrates.
Researchers studied the effects of resveratrol on circadian clock gene expression in young and older human adipose-derived progenitor cells. They found increased levels of some components in older-APCs compared to young-APCs, but also observed gained rhythmicity of some components after resveratrol treatment.
Researchers at the University of Miami Miller School of Medicine have discovered that glioblastoma cells can mimic healthy neurons, evading drugs and immune systems. They identified key enzymes and protein modifications, including BRAF, which shows promise as a potential therapy target.
The Organoid group at the Hubrecht Institute produced the first organoid model of the human conjunctiva, which functions like real human conjunctiva. The researchers discovered a new cell type called tuft cells that become more abundant under allergy-like conditions and play a role in eye's reaction to allergies.
Researchers discuss clonal hematopoiesis, a condition where cells harbor somatic mutations, and its association with aging, solid tumors, and treatment outcomes. Emerging evidence suggests that CH may play a role in cancer development and survival.
A new special issue of Calcified Tissue International & Musculoskeletal Research sheds light on sarcopenia's pathogenesis, clinical implications, and therapeutic targets. Researchers have made significant progress in evaluating, managing, and developing interventions for this condition.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Graphene quantum dots have been designed to enhance catalytic performance using a diatomic doping strategy, resulting in impressive peroxidase-mimicking activity. This metal-free nanozyme has shown high efficacy in inducing apoptosis and ferroptosis of cancer cells with minimal side effects.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A pioneering study published in The American Journal of Pathology reveals the cytoprotective and proregenerative effects of neuropeptide α-MSH in promoting corneal healing after eye injury. The treatment has shown impressive therapeutic potential in reducing the need for corneal transplants.
A study found that patients with refractory large B-cell lymphoma who received bendamustine before CAR T-cell therapy had a shorter progression-free survival and overall response rate compared to those who did not receive bendamustine. The use of bendamustine should be avoided in these patients when possible.
Researchers identified Elovanoid-34, a molecule that modulates the activity of TXNRD1 protein, which regulates antioxidant defenses. This discovery opens new therapeutic avenues for degenerative brain and eye diseases, as well as promoting healthy aging.